A CREST-2 substudy presented at ISC 2026 found that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. Cognitive decline occurred only in patients who experienced a stroke, with no differences between revascularization and medical therapy alone.
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
A review of ClinicalTrials.gov registrations found few late-stage trials with robust sleep outcome measures in elderly Parkinson's disease patients. The analysis in BMC Geriatrics highlights outcome measure heterogeneity, underrepresentation of older adults, and short study durations as key gaps.
Researchers developed BIDSleep, an AI framework that uses Apple Watch data to accurately classify sleep stages, achieving 71% accuracy in a clinical study. Separately, startup SOND launched AI-powered earbuds that track physiological signals to enhance sleep. Both advances demonstrate the expanding role of AI and wearables in sleep science.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
Roche's Elecsys pTau181 test received FDA clearance for primary care use, and its Elecsys ApoE4 test earned CE Mark approval. Despite these advances, Medicare does not cover Alzheimer's blood biomarker screenings before symptoms appear, prompting the bipartisan ASAP Act.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07755631 |
The BASIC-S Feasibility Study for Vascular Risk Reduction |
NOT_YET_RECRUITING | NA |
| NCT07731529 |
Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition |
NOT_YET_RECRUITING | NA |
| NCT07731334 |
Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards |
RECRUITING | NA |
| NCT07716800 |
Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer |
NOT_YET_RECRUITING | |
| NCT07652931 |
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns |
NOT_YET_RECRUITING | NA |
| NCT07623122 |
Characterisation of Functional and Cognitive Responses Following Olfactory Stimulation and/or Functional Training in Older Adults. |
COMPLETED | NA |
| NCT07610109 |
Effects of Comprehensive Community Support Programs on Cognitive Function and Quality of Life in Older Adults |
RECRUITING | |
| NCT07600567 |
Algal Lutein Against Decline of Intellectual Nimbleness |
NOT_YET_RECRUITING | NA |
| NCT07564804 |
A Clinical Trial to Investigate the Efficacy of the Brain Blossom Supplement to Improve Cognitive Function and Memory |
COMPLETED | NA |
| NCT07547319 |
Effects of Accelerated rTMS on Cognitive Function |
RECRUITING | NA |
